Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 6/20 | 0.36 |
| ▸ | MAOB | P27338 | 6/20 | 0.36 |
| ▸ | AOC2 | O75106 | 5/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29058726 | 0.81 | NISCH (0.49) | NISCHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL15108803 | 0.81 | NISCH (0.49) | NISCHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL7616087 | 0.81 | NISCH (0.53) | NISCHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1045627 | 0.81 | NISCH (0.53) | NISCHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17662571 | 0.77 | NISCH (0.45) | NISCHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30739524 | 0.76 | HTT (0.51) | NISCHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL19122732 | 0.75 | NISCH (0.43) | NISCHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL2502594 | 0.75 | NISCH (0.53) | NISCHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL3080227 | 0.74 | NISCH (0.56) | NISCHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17658885 | 0.74 | NISCH (0.42) | NISCHNPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | claimed |
| EP-2131656-A2 | PHTHALAZINE DERIVATIVES | Forest Laboratories Holdings Limited (BM) | 2009-12-16 | — | — | EP | claimed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | claimed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | claimed |
| US-8349836-B2 | Phthalazine derivatives as inhibitors of protein kinase | ARALDI GIAN-LUCA (US) | 2013-01-08 | — | — | US | disclosed |
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | disclosed |
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | ARALDI GIAN-LUCA | 2011-09-29 | — | — | US | disclosed |
| EP-2131656-A2 | PHTHALAZINE DERIVATIVES | Forest Laboratories Holdings Limited (BM) | 2009-12-16 | — | — | EP | disclosed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | disclosed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | NISCH 1332/4885NPC1 2569/4885RAB9A 3930/4885 |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | NISCH 1332/4885NPC1 2569/4885RAB9A 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.